Comparing Bavencio vs Nivolumab
Bavencio (avelumab) | Nivolumab |
|
---|
Bavencio (avelumab) | Nivolumab |
|
|||||||
---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Merkel Cell Carcinoma, Urothelial Carcinoma, Renal Cell Carcinoma. Bavencio may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Head and Neck Cancer, Esophageal Carcinoma, Hepatocellular Carcinoma, Colorectal Cancer, Gastric Cancer, Hodgkin's Lymphoma, Malignant Pleural Mesothelioma, Melanoma, Melanoma -... View more |
Related suggestions Urothelial Carcinoma
Popular comparisons
|
|||||||
More about Bavencio (avelumab) | More about Nivolumab | ||||||||
Ratings & Reviews | |||||||||
Be the first to share your experience with this drug. |
Nivolumab has an average rating of 5.9 out of 10 from a total of 142 ratings on Drugs.com. 54% of reviewers reported a positive effect, while 39% reported a negative effect. |
||||||||
Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||
View all Bavencio side effects |
View all Nivolumab side effects |
||||||||
Drug Class | |||||||||
Generic Availability | |||||||||
N/A |
N/A |
||||||||
Pricing and Coupons * Prices are without insurance | |||||||||
View all Bavencio prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
Dosage Forms | |||||||||
|
N/A |
||||||||
Brand Names | |||||||||
N/A |
Opdivo | ||||||||
Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||
146.4 hours |
640.8 hours |
||||||||
CSA Schedule 1 View glossary of CSA terms | |||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
Pregnancy Category | |||||||||
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||
Drug Interactions | |||||||||
A total of 595 drugs are known to interact with Bavencio:
|
A total of 594 drugs are known to interact with Nivolumab:
|
||||||||
Alcohol/Food/Lifestyle Interactions | |||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
Disease Interactions | |||||||||
First Approval Date | |||||||||
March 23, 2017 |
December 22, 2014 |
||||||||
WADA Class View classifications | |||||||||
N/A |
N/A |
||||||||
More Information | |||||||||
Patient Resources | |||||||||
Professional Resources | |||||||||
Related Treatment Guide | |||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Zynyz
Zynyz is a targeted cancer treatment used to squamous cell carcinoma of the anal canal (SCAC) and ...
Taxol
Taxol (paclitaxel) is used to treat breast cancer, lung cancer, and ovarian cancer. Includes Taxol ...
Keytruda
Keytruda is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Adriamycin
Adriamycin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
Oncovin
Oncovin is used for acute lymphocytic leukemia, acute myeloid leukemia, anaplastic ...
Dactinomycin
Dactinomycin is used for cancer, ewing's sarcoma, osteoarthritis, osteosarcoma, ovarian cancer ...
Vincristine
Vincristine is used for acute lymphocytic leukemia, acute myeloid leukemia, anaplastic ...
Paclitaxel
Paclitaxel is used for breast cancer, breast cancer, adjuvant, breast cancer, metastatic, kaposi's ...
Doxorubicin
Doxorubicin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
Retifanlimab
Retifanlimab is used for anal cancer, merkel cell carcinoma
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.